Search Result

Results for "

CRCs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) AMPK (2) Antibiotic (4) APC (2) Apoptosis (22) Autophagy (3) Bacterial (5) Bcl-2 Family (1) c-Fms (1) c-Myc (2) Carbonic Anhydrase (2) Casein Kinase (1) Caspase (1) CD3 (1) CDK (3) COX (1) CXCR (1) Cyclophilin (1) Cytochrome P450 (3) DNA/RNA Synthesis (1) EGFR (3) Endogenous Metabolite (3) Ephrin Receptor (1) ERK (2) Fungal (4) FXR (1) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (2) Histone Methyltransferase (3) HSP (3) Influenza Virus (2) LAG-3 (1) MDM-2/p53 (3) Microtubule/Tubulin (4) Mitochondrial Metabolism (2) Molecular Glues (1) Neurokinin Receptor (1) NF-κB (5) Oxidative Phosphorylation (1) P-glycoprotein (1) Parasite (4) PD-1/PD-L1 (3) PDK-1 (2) Phosphatase (1) PI3K (3) PPAR (1) PROTACs (1) Pyruvate Kinase (1) Raf (2) Ras (1) Reactive Oxygen Species (6) Ser/Thr Protease (1) SHP2 (1) Somatostatin Receptor (2) STAT (4) STING (1) Topoisomerase (1) Wnt (6) β-catenin (4)
By Research Areas:	Cancer (78) Cardiovascular Disease (2) Infection (11) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N5014

Liensinine perchlorate Maximum Cited Publications 10 Publications Verification	Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
Liensinine Perchlorate is a constituent of?Nelumbo nucifera?Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces?colorectal cancer (CRC) cell apoptosis .

HY-123772

CDK5 inhibitor 20-223 CP668863	CDK	Cancer
CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

HY-139065

AMPC	Others	Cancer
AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .

HY-116572

TASIN-1 hydrochloride	APC	Cancer
TASIN-1 hydrochloride is a selective inhibitor of truncated APC gene (adenomatous polyposis coli gene) and exerts cytotoxic effects through inhibition of cholesterol biosynthesis. TASIN-1 hydrochloride represents a potential strategy for prevention and intervention in CRC with mutant APC .

HY-161826

Antitumor agent-174	β-catenin HSP CDK c-Myc	Cancer
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .

HY-161102

[Ru(phen)2(xant)] hexafluorophosphate	Autophagy	Cancer
[Ru(phen)2(xant)] hexafluorophosphate is an inducer of Autophagy. [Ru(phen)2(xant)] hexafluorophosphate eliminates CRC stem cells by targeting the chaperone Hsp90. [Ru(phen)2(xant)] hexafluorophosphate reduces cell migration and invasion .

HY-108695B

(±)-Enterodiol	Apoptosis Endogenous Metabolite	Cancer
(±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .

HY-108695

Enterodiol	Apoptosis Endogenous Metabolite	Cancer
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .

HY-108695BR

(±)-Enterodiol (Standard)	Apoptosis Endogenous Metabolite	Cancer
(±)-Enterodiol (Standard) is the analytical standard of (±)-Enterodiol. This product is intended for research and analytical applications. (±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .

HY-161140

PI3Kα-IN-16	PI3K Wnt	Cancer
PI3Kα-IN-16 (Z86) is a novel PI3Kα inhibitor with an IC₅₀ value of 4.28 μM. PI3Kα-IN-16 has potent inhibitory efficiency on PI3K-mediated CRCs growth and migration. PI3Kα-IN-16 also inhibits the Wnt signaling pathway .

HY-155068

FC-116	Reactive Oxygen Species Apoptosis Microtubule/Tubulin	Cancer
FC-11 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. FC-11 can also induce endoplasmic reticulum (ER) stress to generate excess reactive oxygen species (ROS), leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-11 can be used in cancer research .

HY-160493

PTK7/β-catenin-IN-6	Wnt β-catenin	Cancer
PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .

HY-107460

LDN-211904 oxalate	Ephrin Receptor	Cancer
LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC₅₀ of 0.079 µM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC .

HY-108433

CPT2 Carnitine palmitoyltransferase 2	Apoptosis MDM-2/p53	Metabolic Disease Cancer
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .

HY-154973

AMPK activator 11	Oxidative Phosphorylation Mitochondrial Metabolism AMPK	Metabolic Disease Cancer
AMPK activator 11 is an AMP-activated protein kinase (AMPK) activator with nanomolelevel antiproliferation activities against several CRCs. AMPK activator 11 selectively inhibits the RKO xenograft growth along by activating AMPK and upregulating oxidative phosphorylation (OXPHOS) ( mitochondrial metabolism ) and can be used for anti-tumor and metabolic disease research .

HY-122347A

Orvepitant maleate GW823296 maleate	Neurokinin Receptor	Neurological Disease
Orvepitant maleate (GW823296 maleate) is potent, selective, orally active and well-tolerated neurokinin-1 receptor (NK-1) antagonist with a pK_i of 10.2 for human neurokinin-1 receptor. Orvepitant maleate can across the blood-brain barrier. Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatment .

HY-147949

SKLB0565	Microtubule/Tubulin Apoptosis	Cancer
SKLB0565 is a potent tubulin inhibitor. SKLB0565 shows significant anti-proliferative activity against CRC (colorectal carcinoma) cell lines, with IC₅₀ values ranging from 0.012 μM to 0.081 μM. SKLB0565 causes G2/M phase arrest and mitochondria-mediated intrinsic apoptosis. SKLB0565 inhibits cell migration and disrupted the tube formation of HUVECs .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-B0294

Flubendazole 5+ Cited Publications	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-B0294R

Flubendazole (Standard)	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-151939

BLM-IN-2	DNA/RNA Synthesis Apoptosis	Cancer
BLM-IN-2 is a Bloom's Syndrome Protein (BLM) inhibitor with an IC₅₀ value of 0.8 μM. BLM-IN-2 effectively suppresses the proliferation, invasion, cell cycle arrest and apoptosis of CRC cells. BLM-IN-2 can be used for the reserarch of colorectal cancer (CRC) .

HY-N2187

Deoxyshikonin 1 Publications Verification	Bacterial HIF/HIF Prolyl-Hydroxylase PI3K Apoptosis	Infection Cardiovascular Disease Cancer
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .

HY-162285

Anticancer agent 189	Akt	Cancer
Anticancer agent 189 (compound 4) is an anticancer agent that antagonizes *CRC* effects by targeting AKT1 .

HY-158050

PXB17	c-Fms	Cancer
PXB17 can inhibit CSF1R (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .

HY-113264

PGD2 ethanolamide	Apoptosis	Cancer
PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .

HY-169348

β-catenin-IN-8	β-catenin Wnt c-Myc	Cancer
β-catenin-IN-8 (Compound 25) is a β-catenin inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits Wnt-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability .

HY-N11777

(−)-N-Hydroxyapiosporamide NHAP	NF-κB	Cancer
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .

HY-153833

PDS-0330 KVA-E-23A	Others	Cancer
PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .

HY-148660

SFI003	Apoptosis Reactive Oxygen Species	Cancer
SFI003 is a SRSF3 inhibitor that drives CRC cell apoptosis via the SRSF3/DHCR24/ROS axis and exhibits potent antitumor effects both in vitro and in vivo .

HY-162516

DBI-2	AMPK Mitochondrial Metabolism	Cancer
DBI-2 is an AMPK activator targeting mitochondrial complex I. DBI-2 disrupts the OXPHOS process, and reduces ATP generation in mitochondria. DBI-2 inhibits the proliferation of colorectal cancer (CRC) cells .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-W181530

NCT02	Molecular Glues CDK	Cancer
NCT02 is a cyclin K molecular glue. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC) .

HY-119261

Ruboxyl	Antibiotic	Cancer
Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .

HY-B0008

Sulindac MK-231	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-116572A

TASIN-1	APC	Cancer
TASIN-1 is a selective inhibitor of truncated *APC* gene (adenomatous polyposis coli gene) and exerts cytotoxic effects through inhibition of cholesterol biosynthesis. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC .

HY-B0008A

Sulindac sodium MK-231 sodium	NF-κB PD-1/PD-L1	Infection Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-158711

STING agonist-38	STING	Cancer
STING agonist-38 (compound 58) is a potent agonist of STING, with the EC₅₀ of 0.05 μM in THP1 cells. STING agonist-38 has certain oral bioactivity .

HY-162955

LSD1/HDAC-IN-1	HDAC Histone Demethylase	Cancer
LSD1/HDAC-IN-1 (compound 2) is a potent inhibitor of HDAC and LSD1, with IC₅₀s of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8 and LSD1, respectively. LSD1/HDAC-IN-1 plays an important role in cancer research .

HY-N3913

Furowanin A	STAT Bcl-2 Family	Cancer
Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .

HY-114977

Avenanthramide A	Reactive Oxygen Species Apoptosis	Cancer
Avenanthramide A is a phytoalexin, which can be found in oats (Avena sativa L.). Avenanthramide A targets the RNA helicase DDX3, leads to mitochondrial swelling and increased ROS production, and induces apoptosis in CRC cells. Avenanthramide A exhibits antitumor efficacy in mouse model. Avenanthramide A orally active .

HY-162148

HNPMI	EGFR	Cancer
HNPMI is an inhibitor of EGFR and has cytotoxic effects on tumor cells. HNPMI can downregulate the protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. HNPMI also regulates BCL-2/BAX and p53 in CRC cell lines to inhibit tumorigenesis .

HY-136541

YB-0158 2 Publications Verification Wnt pathway inhibitor 2	Wnt Apoptosis	Cancer
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .

HY-135103

Tauro-β-muricholic acid sodium 1 Publications Verification T-βMCA sodium	FXR	Cancer
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC₅₀ of 40 μM .

HY-139611B

(S)-MRTX-1719	Histone Methyltransferase	Cancer
(S)-MRTX-1719 (example 16-7) is the S-enantiomer of MRTX-1719. (S)-MRTX-1719 is a PRMT5/MTA complex inhibitor, with an IC₅₀ of 7070 nM .

HY-169098

HSP90/LSD1-IN-1	HSP Histone Demethylase	Cancer
HSP90/LSD1-IN-1 (compound 6) is a HSP90/LSD1 dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

HY-117429

Se-Aspirin Selenium-acetylsalicylic acid	NF-κB	Inflammation/Immunology
Se-Aspirin is a hybrid molecule of selenium and Aspirin (HY-14654). Se-Aspirin reduces the viability of cancer cell lines, particularly colorectal cancer cells .

HY-146254

hCAIX-IN-12	Carbonic Anhydrase Apoptosis Reactive Oxygen Species	Cancer
hCAIX-IN-12 is a potent hCAIX inhibitor with IC₅₀ values of 0.74, 10.78 μM for CAIX and CAII, respectively. hCAIX-IN-12 shows antiproliferative effect and induces apoptosis. hCAIX-IN-12 increases ROS production. hCAIX-IN-12 has the potential for the research of colorectal cancer (CRC) .

HY-B0008R

Sulindac (Standard)	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (Standard) is the analytical standard of Sulindac. This product is intended for research and analytical applications. Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1,666 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,666 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Cat. No.	Product Name	Target	Research Area

HY-P6083

RTSPSSR	Peptides	Others Cancer
RTSPSSR is synthesized peptide, which binds specifically to claudin-1 and visulizes the CRC tumor in mice, through near-infrared fluorescence imaging .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P10596

Lasioglossin-III	Bacterial Fungal	Infection Cancer
Lasioglossin-III is an antimicrobial peptide that can be isolated from the venom of wild bees. Lasioglossin-III has high antibacterial activity against Gram-positive and Gram-negative bacteria, antifungal activity and antitumor activity. Lasioglossin-III has certain cytotoxicity against three cancer cell lines (HeLa S3, CRC SW 480 and CCRF-CEM T) with IC₅₀ values of 4, 18 and 5 μM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81973

	POLD1 Antibody (YA1718) CDC2; CRCs10; MDPL; POLD; POLD1	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	POLD1 Antibody (YA1718) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1718), targeting POLD1, with a predicted molecular weight of 124 kDa (observed band size: 124 kDa). POLD1 Antibody (YA1718) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification